Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study science science / science 4 years ago 290 Views comments Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year. Read more
Comments